Metastatic Prostate Cancer Presented with Stauffer Syndrome-Like Paraneoplastic Cholestasis: A Case Report
Article Sidebar
Main Article Content
Abstract
Prostate cancer is common cancer diagnosed in men, primarily affecting those older than 60 years. Bone metastasis, which is the most frequent metastatic site, significantly reduce survival time. We present the case of an 83-year-old Thai male diagnosed with advanced prostate cancer and bone marrow metastasis who developed jaundice. Laboratory results show anemia, thrombocytopenia, and unexplained cholestasis. Viral hepatitis and autoimmune hepatitis were excluded. Magnetic resonance imaging with magnetic resonance cholangiopancreatography showed no biliary obstruction. Bone marrow biopsy confirmed metastatic prostate cancer. Due to anemic symptoms and fatigue, only medical castration was chosen as first-line treatment. 2 months after treatment, the patient had significantly improved in anemia, thrombocytopenia, bilirubin level, prostate-specific antigen levels, and clinical status. The patient can well tolerate the treatment. This improvement is consistent with Stauffer syndrome-like; a paraneoplastic syndrome most often associated with renal cell carcinoma but rarely reported in prostate cancer.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles in this journal are copyrighted by the x may be read and used for academic purposes, such as teaching, research, or citation, with proper credit given to the author and the journal.use or modification of the articles is prohibited without permission.
statements expressed in the articles are solely the opinions of the authors.
authors are fully responsible for the content and accuracy of their articles.
other reuse or republication requires permission from the journal."
References
Balajisubramanian S, Sitaraman B. Stauffer syndrome: a comprehensive review of the icteric variant of the syndrome. Cureus 2019;11(10): e6032. doi: 10.7759/cureus.6032.
Chavarriaga J, Fakih N, Cataño JC, Villaquiran C, Rodriguez S, Patino G. Stauffer syndrome, clinical implications and knowledge gaps, does size matter? Case report. BMC Urol 2020;20(1):105. doi: 10.1186/s12894-020-00671-w.
Ikuerowo SO, Ojewuyi OO, Omisanjo OA, Abolarinwa AA, Bioku MJ, Doherty AF. Paraneoplastic syndromes and oncological outcomes in renal cancer. Niger J Clin Pract 2019;22(9):1271-5. doi: 10.4103/njcp.njcp_35_19.
Ertuğrul İ, Başar Ö, Ödemiş B, Yüksel İ, Dişibeyaz S, Turhan N, et al. Paraneoplastic cholestasis in prostate carcinoma: a case report and review of the literature. Turkiye Klinikleri J Med Sci 2010;30(5):1756-9. doi: 10.5336/medsci.2008-10266.
Vieira AC, Alvarenga MJ, Santos JC, Silva AM. Paraneoplastic jaundice and prostate cancer. BMJ Case Rep 2017;2017:bcr2016218001. doi: 10.1136/bcr-2016-218001.
Hagood KW, Snyders TL, Amaria RN, Mansoor AM. Prostate cancer and liver dysfunction: a case of cytokine dysregulation. J Pain Symptom Manage 2007;34(3):225-6. doi: 10.1016/j.jpainsymman.2007.05.003.
Khanal S, Bhatt T, Atogwe ID, Itare V, Shrestha E, Sulh M. Stauffer syndrome as the initial presentation of advanced metastatic prostate cancer. Cureus 2023;15(4):e37663. doi: 10.7759/cureus.37663.
Fontes-Sousa M, Magalhães H, da Silva FC, Maurício MJ. Stauffer’s syndrome: a comprehensive review and proposed updated diagnostic criteria. Urol Oncol 2018;36(7):321-6. doi: 10.1016/j.urolonc.2018.01.019.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomized, double-blind, phase 3 trial. Lancet Oncol 2019;20(5):686-700. doi: 10.1016/S1470-2045(19)30082-8.
Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomized, open-label, phase 3 trial. Lancet Oncol 2013;14(2):149-58. doi: 10.1016/S1470-2045(12)70560-0.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemo hormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373(8):737-46. doi: 10.1056/NEJMoa1503747.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarmed, multistage, platform randomized controlled trial. Lancet 2016;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5.
